A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy - Wikidata - thesis-toulmin - TriplyDB

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy

http://www.wikidata.org/entity/Q33932800

about

Vitamin B and its derivatives for diabetic kidney disease Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial Evidence for altered thiamine metabolism in diabetes: Is there a potential to oppose gluco- and lipotoxicity by rational supplementation?Pharmacokinetics of high-dose oral thiamine hydrochloride in healthy subjects Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy Diabetic cardiac autonomic neuropathy: Do we have any treatment perspectives?Paraptosis cell death induction by the thiamine analog benfotiamine in leukemia cells Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.The impact of thiamine treatment in the diabetes mellitus.Biochemical changes correlated with blood thiamine and its phosphate esters levels in patients with diabetes type 1 (DMT1)Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes.Novel drugs and intervention strategies for the treatment of chronic kidney disease.Metabolic Benefits of Six-month Thiamine Supplementation in Patients With and Without Diabetes Mellitus Type 2.Glycation in diabetic nephropathy.Diabetic nephropathy in 2010: Alleviating the burden of diabetic nephropathy.Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy.Thiamine deficiency in diabetes mellitus and the impact of thiamine replacement on glucose metabolism and vascular disease.New approaches to the treatment of nephropathy in diabetes.Advanced glycation end products and diabetic retinopathy.What are new avenues for renal protection, in addition to RAAS inhibition?Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.Current therapeutic interventions in the glycation pathway: evidence from clinical studies.Emerging drugs for managing kidney disease in patients with diabetes.Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.The pathobiology of diabetic vascular complications--cardiovascular and kidney disease.Therapeutic approaches to diabetic nephropathy--beyond the RAS.Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?Novel effective drugs for diabetic kidney disease? or not?The inhibitory activities of the edible green alga Capsosiphon fulvescens on rat lens aldose reductase and advanced glycation end products formation.Targeting advanced glycation with pharmaceutical agents: where are we now?Benfotiamine increases glucose oxidation and downregulates NADPH oxidase 4 expression in cultured human myotubes exposed to both normal and high glucose concentrations.Coenzyme Q10 prevents GDP-sensitive mitochondrial uncoupling, glomerular hyperfiltration and proteinuria in kidneys from db/db mice as a model of type 2 diabetes

P2860

Q24186641-E6A9A723-AC06-452A-8135-393990DF16EC Q26782422-BF385A6A-157F-4ABC-9BC8-E87755C8D5E4 Q28086840-6A5C9625-BB3B-4E87-862B-4905FE79B90D Q28546969-E0BA47A3-6C59-41DB-AD0E-05779290DBC4 Q33759560-77B9B701-19C8-40FC-AC62-CBF80191B670 Q34150624-59D74DFC-B683-4681-8965-F40BD04755F3 Q34336244-337F90D8-8E07-4C18-9646-79229DE6CD90 Q35179226-CAF84086-E09D-4BE0-95D6-F7D530C0286B Q35596628-14C6F30A-C7ED-4D7C-8701-6F039DEDF0F0 Q35809946-70ACF511-9303-42AA-89C8-3CBB66071CEA Q36038031-066E568E-CC5C-4FDD-93CE-9EB086E8A130 Q36375541-EA6C1651-CC2D-4F98-8537-FD9C35D4F200 Q36725829-1226D50D-ACAA-4180-9D06-3D30CC0C9EFD Q37219043-F9FBB217-2B34-4730-B69C-D8986B44B773 Q37577900-6E9A06F8-8742-4B35-BD2D-B2509DF6CF1E Q37801858-9B89748E-0FFA-45B9-88B0-C51F550E6720 Q37833489-41008D7D-CCE6-445C-BD5C-EBDE92A83255 Q37845940-AA44E67C-EA1B-4B39-97FB-82A3472F132B Q37874695-9AB0CDCC-19D5-4E9B-85A6-423329D5CE10 Q37899907-97DE9FEF-46E3-4E07-AF0A-8E9E75F4CA0C Q37930514-49EE2275-B7AB-484D-B6A1-96A3064F4379 Q37980677-32969870-1005-45B1-9CD9-04F8CB7BA1D1 Q38006722-436A4E11-D20D-4BEA-BD20-B99A9A473358 Q38070906-01236B26-2AEA-4D56-9EC8-C6D09229AB50 Q38075029-955ECA3F-A98F-4716-AAEE-B42108C9C9A4 Q38096444-D2EF9414-4C59-44CF-BFE7-FD20413B573A Q38200957-4C3953E6-F548-4BB6-9013-883C70F1AE05 Q38209811-A4285E2F-8247-4CDD-9899-66978805D446 Q38243632-B5382353-26AF-4E3F-AA32-AF482FC492A9 Q38265818-1CC282D8-26DA-4D54-8036-41FDC70B3998 Q38451453-5A91E27E-631C-4CD4-96AD-50D81220E557 Q38890348-52676234-3C81-4013-BF2A-F3240B5BA319 Q42116189-178D0761-3B57-4F75-A34A-EF82A6D89CC0 Q58329660-4F75C8AA-B39F-4E85-9CE3-556FA462C60E

P2860

A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy

http://www.wikidata.org/entity/Q33932800

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A double-blind, randomized, pl ...... ents with diabetic nephropathy

@ast

A double-blind, randomized, pl ...... ents with diabetic nephropathy

@en

type

label

A double-blind, randomized, pl ...... ents with diabetic nephropathy

@ast

A double-blind, randomized, pl ...... ents with diabetic nephropathy

@en

prefLabel

A double-blind, randomized, pl ...... ents with diabetic nephropathy

@ast

A double-blind, randomized, pl ...... ents with diabetic nephropathy

@en

P1433

Q33932800-37721809-339D-4FE4-9E48-DD09C20E80D6

P1476

Q33932800-36EC837C-9DC9-47C1-AEF1-2497EBC957D8

P2093

Q33932800-01A8F2F1-8ACD-4679-958A-EABBA74D04AA

Q33932800-1957CB3E-F6B0-4F41-A250-AD2B5A0B2AC8

Q33932800-228AAFD1-8A85-492C-8A1F-98B6F22AA2F3

Q33932800-3730E7C1-BAFE-4EAA-9AE0-1EB67EBFEE03

Q33932800-43C3C4D9-C655-4C3B-B49F-AB4E8C6CEFA4

Q33932800-59ED693A-BCB8-4AC1-9FE2-7AFBCB6B8F74

Q33932800-7E436537-245B-4254-98AD-898694CEA481

Q33932800-95DE0A0C-036F-43CA-9B5B-1213C95D56C9

Q33932800-CA60C17F-B84C-4443-B5A7-BE9C15BF5B55

Q33932800-DB72F641-63B7-449E-8DF3-6A9668DBB3BE

P2860

Q33932800-05AD71D3-BF22-4084-9A41-7DFA1BAD2FB3

Q33932800-13AB1FC4-BEE8-4001-B837-12EBF3C8190D

Q33932800-29C79BE8-7FF4-4AA4-ABDB-2FA1B867D7E4

Q33932800-3489EFB7-B83B-498E-9A39-0D2756359A40

Q33932800-456090E5-19FC-4BF1-8707-C91FA3953CA6

Q33932800-7CE82A23-7A6F-41D7-8E12-034AF533D302

Q33932800-92DD4D8F-1965-4D6A-9728-2FF23F705B46

Q33932800-BD3B8C86-6B73-40C4-AC1C-89869D6054B8

Q33932800-C310028B-945C-481F-98C8-8AA7B534A9DA

Q33932800-D155CB9C-309B-4A92-8DA3-47EAAA2B5E6D

P304

Q33932800-F4A5EF30-B87F-4509-B7BB-55898598B265

P31

Q33932800-733EDA05-48BB-4334-8831-70688A6F2D91

P356

Q33932800-F1A0A4A6-71E0-4658-B3FA-D19A27AD03C2

P407

Q33932800-D287BBDD-B6B8-4850-A686-7E496F67C454

P433

Q33932800-D0118D51-C574-4D06-9BE4-5AEEEE97E7DA

P478

Q33932800-DC50547F-5C6A-4DF8-B912-D9BA5D3B52C5

P577

Q33932800-C1DC8295-A778-469C-86ED-94818417179C

P5875

Q33932800-A51C37FB-AF0E-4C5B-9F5C-CEB16386919C

P698

Q33932800-BC2E95FE-752E-4788-B7CD-0322751216A0

P921

Q33932800-82E49864-739E-4183-B836-DA5EA0A58A5B

P932

Q33932800-072AFE6C-316E-4585-A33C-A19771EEBDDC

P356

P1433

P1476

A double-blind, randomized, pl ...... ents with diabetic nephropathy

@en

P2093

Alaa Alkhalaf

http://www.w3.org/2001/XMLSchema#string

Astrid Klooster

http://www.w3.org/2001/XMLSchema#string

G Sophie Mijnhout

http://www.w3.org/2001/XMLSchema#string

Gerjan J Navis

http://www.w3.org/2001/XMLSchema#string

Henk J G Bilo

http://www.w3.org/2001/XMLSchema#string

Nanne Kleefstra

http://www.w3.org/2001/XMLSchema#string

Reinold O B Gans

http://www.w3.org/2001/XMLSchema#string

Robbert J Slingerland

http://www.w3.org/2001/XMLSchema#string

Stephan J L Bakker

http://www.w3.org/2001/XMLSchema#string

Ulrike Achenbach

http://www.w3.org/2001/XMLSchema#string

P2860

High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

Tubulointerstitial changes as a major determinant in the progression of renal damage.

Renal protection in diabetes: role of glycemic control.

High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients.

The measurement of erythrocyte transketolase activity on a discrete analyser.

High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study.

Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?

P304

1598-1601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-2241

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2010-04-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43299127

http://www.w3.org/2001/XMLSchema#string

P698

20413516

http://www.w3.org/2001/XMLSchema#string

P921

P932

2890365

http://www.w3.org/2001/XMLSchema#string